Bisphosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases
View Patent ↗Bisphosphonate compounds and related methods of making and using are disclosed, including pyridinium-1-yl, quinolinium-1-yl, and related compounds. The activity of compounds is disclosed in the context of functional assays such as Leishmania major farnesyl diphosphate synthase (FPPS) inhibition, Dictyostelium discoideum growth inhibition, human gamma delta T cell activation, and bone resorption. The applicability of bisphosphonate compounds in the context of parasitic infections, for example against trypanosomes, is disclosed. Further potential applications of the invention are disclosed regarding the treatment of one or more conditions such as bone resorption disorders, cancer, bone pain, infectious diseases, and in immunotherapy.
1. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of one or more compounds having the formula:
or pharmaceutically acceptable salts thereof;
wherein:
X is —OH, or a halogen;
n is 1, 2, or 3;
R 1 -R 5 , independently of one another, are selected from the group consisting of a hydrogen, a halogen, a —CN, —OR 10 , —COOR 10 , —OCOOR 10 , —COR 10 , —CON(R 10 ) 2 , —OCON(R 10 ) 2 , —N(R 10 ) 2 , —NO 2 , —SR 10 , —SO 2 R 10 , —SO 2 N(R 10 ) 2 or —SOR 10 group, an optionally substituted alkyl group, an optionally substituted alkenyl group, and an optionally substituted aryl group, where each R 10 is selected from H, an optionally substituted alkyl group and an optionally substituted aryl group, an optionally substituted acyl group;
R 6 and R 7 , independently of each other, are selected from the group consisting of a hydrogen, a halogen, a —N(R 11 ) 2 , or —SR 11 group, an optionally substituted alkyl group, an optionally substituted alkenyl group, an optionally substituted alkoxy group, and an optionally substituted aryl group, where each R 11 is selected from H, an optionally substituted alkyl group and an optionally substituted aryl group; and
wherein R 6 and R 7 can together form a 3-7-member ring which may contain one or more double bonds.
2. The pharmaceutical composition of claim 1 wherein the alkyl, alkenyl or aryl groups are optionally substituted with one or more halogens, —CN, —COOR″, —OR″, —COR″, —OCOOR″, —CON(R″) 2 , —OCON(R″) 2 , —N(R″) 2 , —NO 2 , —SR″, —SO 2 R″, —SO 2 N(R″) 2 , —SOR″, alkyl, alkenyl, or aryl groups, where each R″, independently, is hydrogen, an alkyl group, alkenyl group or aryl group.
3. The pharmaceutical composition of claim 2 wherein at least one of R 2 , R 3 or R 4 is selected from the group consisting of an optionally substituted alkyl group having 4-20 carbon atoms, an optionally substituted alkenyl group having 2-20 carbon atoms, and an —OR 10 group where R 10 is selected from an optionally substituted alkyl group having 1-20 carbon atoms.
4. The pharmaceutical composition of claim 2 wherein X is OH.
5. The pharmaceutical composition of claim 2 wherein X is OH, n=1, and R 6 and R 7 are H.
6. The pharmaceutical composition of claim 5 wherein at least one of R 2 , R 3 or R 4 is selected from the group consisting of an optionally substituted alkyl group having 4-20 carbon atoms, and an —OR 10 group, where R 10 is selected from an optionally substituted alkyl group having 4-20 carbon atoms.
7. The pharmaceutical composition of claim 5 wherein R 2 is an alkyl group having 4-10 carbon atoms.
8. The pharmaceutical composition of claim 5 wherein R 2 is an alkyl group having 10-20 carbon atoms.
9. The pharmaceutical composition of claim 5 wherein all of R 1 and R 3 -R 7 are hydrogens, and R 2 is selected from the group consisting of alkyl groups having 4-20 carbon atoms, and —OR 10 groups where R 10 is an alkyl group having 4-20 carbon atoms.
10. The pharmaceutical composition of claim 2 wherein X is a halogen.
11. The pharmaceutical composition of claim 2 wherein X is a halogen, n=1 and R 6 and R 7 are H.
12. The pharmaceutical composition of claim 11 wherein X is Cl.
13. The pharmaceutical composition of claim 11 wherein X is F.
14. The pharmaceutical composition of claim 11 wherein at least one of R 2 , R 3 or R 4 is selected from the group consisting of an —OR 10 group, where R 10 is selected from an alkyl group having 4-20 carbon atoms.
15. A pharmaceutical composition of claim 1 comprising one or more compounds or pharmaceutically acceptable salts thereof wherein the compound have a formula selected from:
16. A method of treating cancer comprising administering to a patient in need thereof a therapeutically effective amount of one or more compounds having the formula:
or pharmaceutically acceptable salts thereof;
wherein:
X is —OH, or a halogen;
n is 1, 2, or 3;
R 1 -R 5 , independently of one another, are selected from the group consisting of a hydrogen, a halogen, a —CN, —OR 10 , —COOR 10 , —OCOOR 10 , —COR 10 , —CON(R 10 ) 2 , —OCON(R 10 ) 2 , —N(R 10 ) 2 , —NO 2 , —SR 10 , —SO 2 R 10 , —SO 2 N(R 10 ) 2 or —SOR 10 group, an optionally substituted alkyl group, an optionally substituted alkenyl group, and an optionally substituted aryl group, where each R 10 is selected from H, an optionally substituted alkyl group and an optionally substituted aryl group, an optionally substituted acyl group;
R 6 and R 7 , independently of each other, are selected from the group consisting of a hydrogen, a halogen, a —N(R 11 ) 2 , or —SR 11 group, an optionally substituted alkyl group, an optionally substituted alkenyl group, an optionally substituted alkoxy group, and an optionally substituted aryl group, where each R 11 is selected from H, an optionally substituted alkyl group and an optionally substituted aryl group; and
wherein R 6 and R 7 can together form a 3-7-member ring which may contain one or more double bonds; and
wherein the cancer is selected from breast cancer, a bone metastatic condition, myeloma, lymphoma, prostate cancer, or an epidermoid cancer.
17. The method of claim 16 wherein the cancer is breast cancer.
18. The method of claim 17 wherein the breast cancer involves an actual or potential bone metastatic condition.
19. The method of claim 16 wherein the cancer is a bone metastatic condition.
20. The method of claim 16 wherein the cancer is prostate cancer.
21. The method of claim 16 wherein the cancer is myeloma or lymphoma.
22. The method of claim 16 wherein in the formula, X is OH.
23. The method of claim 22 wherein in the formula, n=1, and R 6 and R 7 are H.
24. The method of claim 23 , wherein in the formula, at least one of R 2 , R 3 or R 4 is selected from the group consisting of an optionally substituted alkyl group having 4-20 carbon atoms, and an —OR 10 group, where R 10 is selected from an optionally substituted alkyl group having 4-20 carbon atoms.
25. The method of claim 23 wherein R 2 is an alkyl group having 4-10 carbon atoms.
26. The method of claim 23 wherein R 2 is an alkyl group having 10-20 carbon atoms.
27. A method of treating an infectious disease comprising administering to a patient in need thereof a therapeutically effective amount of one or more compounds having the formula:
or pharmaceutically acceptable salts; wherein:
X is —OH, or a halogen;
n is 1, 2, or 3;
R 1 -R 5 , independently of one another, are selected from the group consisting of a hydrogen, a halogen, a —CN, —OR 10 , —COOR 10 , —OCOOR 10 , —COR 10 , —CON(R 10 ) 2 , —OCON(R 10 ) 2 , —N(R 10 ) 2 , —NO 2 , —SR 10 , —SO 2 R 10 , —SO 2 N(R 10 ) 2 or —SOR 10 group, an optionally substituted alkyl group, an optionally substituted alkenyl group, and an optionally substituted aryl group, where each R 10 is selected from H, an optionally substituted alkyl group and an optionally substituted aryl group, an optionally substituted acyl group;
R 6 and R 7 , independently of each other, are selected from the group consisting of a hydrogen, a halogen, a —N(R 11 ) 2 , or —SR 11 group, an optionally substituted alkyl group, an optionally substituted alkenyl group, an optionally substituted alkoxy group, and an optionally substituted aryl group, where each R 11 is selected from H, an optionally substituted alkyl group and an optionally substituted aryl group; and
wherein R 6 and R 7 can together form a 3-7-member ring which may contain one or more double bonds; and
wherein the infectious disease is leishmaniasis, toxoplasmosis, cryptosporidiosis, sleeping sickness, or malaria.
28. The method of claim 27 wherein said infectious disease is due to Trypanosoma or Leishmania parasites.
29. The method of claim 27 wherein, in the formula, X is OH.
30. The method of claim 29 wherein, in the formula, n=1, and R 6 and R 7 are H.
31. The method of claim 30 wherein, in the formula, at least one of R 2 , R 3 or R 4 is selected from the group consisting of an optionally substituted alkyl group having 4-20 carbon atoms, and an —OR 10 group, where R 10 is selected from an optionally substituted alkyl group having 4-20 carbon atoms.
32. The method of claim 30 wherein R 2 is an alkyl group having 4-10 carbon atoms.
33. A method of treating a bone resorption disorder comprising administering to a patient in need thereof, a therapeutically effective amount of one or more compounds having the formula:
or pharmaceutically acceptable salts thereof;
wherein:
X is —OH, or a halogen;
n is 1, 2, or 3;
R 1 -R 5 , independently of one another, are selected from the group consisting of a hydrogen, a halogen, a —CN, —OR 10 , —COOR 10 , —OCOOR 10 , —COR 10 , —CON(R 10 ) 2 , —OCON(R 10 ) 2 , —N(R 10 ) 2 , —NO 2 , —SR 10 , —SO 2 R 10 , —SO 2 N(R 10 ) 2 or —SOR 10 group, an optionally substituted alkyl group, an optionally substituted alkenyl group, and an optionally substituted aryl group, where each R 10 is selected from H, an optionally substituted alkyl group and an optionally substituted aryl group, an optionally substituted acyl group;
R 6 and R 7 , independently of each other, are selected from the group consisting of a hydrogen, a halogen, a —N(R 11 ) 2 , or —SR 11 group, an optionally substituted alkyl group, an optionally substituted alkenyl group, an optionally substituted alkoxy group, and an optionally substituted aryl group, where each R 11 is selected from H, an optionally substituted alkyl group and an optionally substituted aryl group; and
wherein R 6 and R 7 can together form a 3-7-member ring which may contain one or more double bonds.
34. The method of claim 33 wherein, in the formula, X is OH.
35. A method for stimulating γδ T cells which comprises the step of contacting γδ T cells with an effective amount of a compound having the formula
or pharmaceutically acceptable salts thereof;
wherein:
X is —OH, or a halogen;
n is 1, 2, or 3;
R 1 -R 5 , independently of one another, are selected from the group consisting of a hydrogen, a halogen, a —CN, —OR 10 , —COOR 10 , —OCOOR 10 , —COR 10 , —CON(R 10 ) 2 , —OCON(R 10 ) 2 , —N(R 10 ) 2 , —NO 2 , —SR 10 , —SO 2 R 10 , —SO 2 N(R 10 ) 2 or —SOR 10 group, an optionally substituted alkyl group, an optionally substituted alkenyl group, and an optionally substituted aryl group, where each R 10 is selected from H, an optionally substituted alkyl group and an optionally substituted aryl group, an optionally substituted acyl group;
R 6 and R 7 , independently of each other, are selected from the group consisting of a hydrogen, a halogen, a —N(R 11 ) 2 , or —SR 11 group, an optionally substituted alkyl group, an optionally substituted alkenyl group, an optionally substituted alkoxy group, and an optionally substituted aryl group, where each R 11 is selected from H, an optionally substituted alkyl group and an optionally substituted aryl group; and
wherein R 6 and R 7 can together form a 3-7-member ring which may contain one or more double bonds.
36. The method of claim 35 wherein, in the formula, X is OH.
37. The method of claim 36 wherein, in the formula, n=1, and R 6 and R 7 are H.
38. The method of claim 37 wherein, in the formula, at least one of R 2 , R 3 or R 4 is selected from the group consisting of an optionally substituted alkyl group having 4-20 carbon atoms, and an —OR 10 group, where R 10 is selected from an optionally substituted alkyl group having 4-20 carbon atoms.
39. The method of claim 37 wherein R 2 is an alkyl group having 4-10 carbon atoms.